Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO; Japanese Ixekizumab Study Group. Saeki H, et al. Among authors: ishii t. J Dermatol. 2017 Apr;44(4):355-362. doi: 10.1111/1346-8138.13622. Epub 2016 Oct 11. J Dermatol. 2017. PMID: 27726163 Free PMC article. Clinical Trial.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Taylor PC, et al. Among authors: ishii t. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. N Engl J Med. 2017. PMID: 28199814 Free article. Clinical Trial.
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, Saifan CG, Issa M, Isaka Y, Akashi N, Ishii T, Tanaka Y. Harigai M, et al. Among authors: ishii t. Mod Rheumatol. 2020 Jan;30(1):36-43. doi: 10.1080/14397595.2019.1583711. Epub 2019 Mar 21. Mod Rheumatol. 2020. PMID: 30784354 Clinical Trial.
Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study.
Okamoto N, Atsumi T, Takagi M, Takahashi N, Takeuchi T, Tamura N, Nakajima A, Nakajima A, Fujii T, Matsuno H, Ishii T, Tsujimoto N, Nishikawa A, Minatoya M, Tanaka Y, Kuwana M. Okamoto N, et al. Among authors: ishii t. Mod Rheumatol. 2024 Aug 9:roae064. doi: 10.1093/mr/roae064. Online ahead of print. Mod Rheumatol. 2024. PMID: 39119689
Enhanced local production of osteopontin in rheumatoid joints.
Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, Murata N, Nomura S, Matsuno H, Katayama R, Kon S, Inobe M, Uede T, Kawase I, Saeki Y. Ohshima S, et al. Among authors: ishii t. J Rheumatol. 2002 Oct;29(10):2061-7. J Rheumatol. 2002. PMID: 12375312
4,471 results